Page 1 of Clinical Trials for Drug Montanide ISA-51, 125 Total Matches

Show/Hide Clinical Trials Which are Not Seeking New Volunteers

1
Completed
Safety and Immunogenicity Study of Plasmodium Vivax CS Derived Synthetic Peptides Formulated in Two Adjuvants
Last Updated: March 5, 2010
Condition(s): Malaria, Vivax
2
Terminated
Vaccination With Tetanus and KLH to Assess Immune Responses.
Last Updated: March 26, 2012
Condition(s): Cancer
3
Completed
Lymphocyte-Depleting Nonmyeloablative Preparative Chemotherapy Followed By Autologous Lymphocyte Infusion, Peptide Vaccine Plus Montanide ISA-51, and Interleukin-2 in Treating Patients With Metastatic Melanoma
Last Updated: February 6, 2009
Condition(s): Melanoma (Skin)
4
Completed
Monoclonal Antibody Therapy and Vaccine Therapy in Treating Patients With Resected Stage III or Stage IV Melanoma
Last Updated: April 23, 2010
Condition(s): Intraocular Melanoma; Melanoma (Skin)
5
Recruiting
Phase I Oncovir Poly IC:LC and NY-ESO-1/gp100/MART
Last Updated: February 20, 2012
Condition(s): Melanoma
6
Completed
Evaluation of the Impact of Adjuvants Accompanying Peptide Immunization in High-Risk Melanoma
Last Updated: July 15, 2010
Condition(s): High-Risk Melanoma
7
Terminated
Continuation Booster Trial After a Vaccine Combining Tyrosinase/GP100/MART-1 Peptides Emulsified With Montanide ISA 51 With or Without GM-CSF for Patients With Melanoma
Last Updated: January 17, 2008
Condition(s): Melanoma
8
Not yet recruiting
Survivin Vaccine Therapy for Patients With Malignant Gliomas
Last Updated: January 11, 2012
Condition(s): Adult Anaplastic Astrocytoma; Adult Anaplastic Oligodendroglioma; Adult Giant Cell Glioblastoma; Adult Glioblastoma; Adult Gliosarcoma; Adult Mixed Glioma; Recurrent Adult Brain Tumor
9
Completed
Fludarabine Followed by Vaccine Therapy and White Blood Cell Infusions in Treating Patients With Unresectable or Metastatic Melanoma
Last Updated: March 25, 2010
Condition(s): Melanoma (Skin)
10
Recruiting
Novel Adjuvants for Peptide-Based Melanoma Vaccines
Last Updated: June 23, 2005
Condition(s): Melanoma
11
Completed
A Pilot Study of NY-ESO-1b Peptide Plus CpG 7909 and Montanide ISA-51 in Patients With Cancer.
Last Updated: August 21, 2006
Condition(s): Cancer; Neoplasm
12
Completed
Lymphocyte Re-infusion During Immune Suppression to Treat Metastatic Melanoma
Last Updated: July 15, 2010
Condition(s): Melanoma; Neoplasm Metastasis
13
Active, not recruiting
Vaccine Therapy With or Without Cyclophosphamide in Treating Patients Who Have Undergone Surgery for Stage II, Stage III, or Stage IV Melanoma
Last Updated: February 6, 2009
Condition(s): Melanoma (Skin)
14
Not yet recruiting
A Multipeptide Vaccine Plus Toll-Like Receptor Agonists in Melanoma Patients
Last Updated: April 24, 2012
Condition(s): Melanoma
15
Completed
Evaluation of the Effects of Local Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF) in Adjuvant Administration on Dendritic Cells in Skin of Melanoma Patients and in Sentinel Lymph Nodes: MEL38
Last Updated: June 2, 2009
Condition(s): Melanoma
16
Completed
flt3L With or Without Vaccine Therapy in Treating Patients With Metastatic Melanoma or Renal Cell Cancer
Last Updated: March 1, 2007
Condition(s): Stage IV Melanoma; Stage IV Renal Cell Cancer; Recurrent Renal Cell Cancer; Recurrent Melanoma
17
Completed
Vaccine Therapy in Treating Patients With Metastatic Melanoma of the Eye
Last Updated: March 2, 2007
Condition(s): Extraocular Extension Melanoma; Recurrent Intraocular Melanoma
18
Active, not recruiting
Proteinase 3 PR1 Peptide Mixed With Montanide ISA-51 VG Adjuvant and Administered With GM-CSF and PEG-INTRON(R)
Last Updated: March 22, 2012
Condition(s): Leukemia
19
Active, not recruiting
Randomized, Double Blind, Placebo-controlled Topical Resiquimod Adjuvant for NY-ESO-1 Protein Vaccination
Last Updated: February 17, 2010
Condition(s): Tumors
20
Terminated
Immunization of Disease-Free Melanoma Patients With Different HLA-A2 Peptides
Last Updated: October 14, 2010
Condition(s): Melanoma

Clinical Trials content is provided directly by the U.S. National Institutes of Health via ClinicalTrials.gov and is not reviewed separately by ClinicalTrialsFeeds.org. Every page of specific clinical trials information contains a unique identifier which can be used to find further details directly from the National Institutes of Health.

The URL of this page is: http://clinicaltrialsfeeds.org/clinical-trials/results/?term=Drug+Montanide+ISA-51

Page 1 of Clinical Trials for Drug Montanide ISA-51, 125 Total Matches

Get the Latest Results via Email or RSS

Subscribe via Web Newsreaders

Browse

Clinical Trials Background

About